The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en.
We have previously described a 4-guanidino-Neu5Ac2en (zanamivir)-resistant neuraminidase (NA) variant G70C4-G, with an active site mutation Glu 119 to Gly. This variant has been found to also harbor a hemagglutinin (HA) mutation in the receptor binding site, Ser 186 to Phe. Examination of early passages of the G70C4-G virus revealed that this HA mutation had arisen by the first passage. From a subsequent passage two transient variants were isolated which had each acquired a different second HA mutation, Ser 165 to Asn and Lys 222 to Thr. Both were highly drug resistant and drug dependent and their ability to adsorb to and penetrate cells was decreased. Comparison of drug sensitivities between the variant, with the additional HA mutation at Ser 165, and viruses with either mutation alone revealed that these two HA mutations acted synergistically to increase resistance. To determine the contribution to resistance of each of the NA and HA mutations in G70C4-G, the NA mutation was separated from the HA mutation by reassorting. The NA mutation and the HA mutation each conferred low-level resistance to zanamivir, while the two mutations interacted synergistically in the double mutant to give higher resistance in vitro. Infectivity was not adversely affected in the double mutant and while there was a small decrease in sensitivity to zanamivir in the mouse model, there was no detectable resistance to zanamivir in the ferret model.
Blick
T J
TJ
Glaxo Wellcome Research and Development Ltd., Stevenage, Hertfordshire, United Kingdom. Tony.Blick@bioresi.com.au
Sahasrabudhe
A
A
McDonald
M
M
Owens
I J
IJ
Morley
P J
PJ
Fenton
R J
RJ
McKimm-Breschkin
J L
JL
D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage; D002460:Cell Line; D004252:DNA Mutational Analysis; D004285:Dogs; D004352:Drug Resistance, Microbial / Q000235:genetics; D005260:Female; D005289:Ferrets; D005814:Genes, Viral / Q000235:genetics; D006146:Guanidines; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D009154:Mutation / Q000502:physiology*; D009439:Neuraminidase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000494:pharmacology; D009975:Orthomyxoviridae / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D009976:Orthomyxoviridae Infections / Q000188:drug therapy; D011714:Pyrans; D012794:Sialic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D010948:Viral Plaque Assay; D015678:Viral Structural Proteins / Q000235:genetics; D014779:Virus Replication / Q000187:drug effects; D053243:Zanamivir
D000998:Antiviral Agents; D006146:Guanidines; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D011714:Pyrans; D012794:Sialic Acids; D015678:Viral Structural Proteins; D009439:Neuraminidase; D053243:Zanamivir